ArticleStem cells international2011
Stem cell-based approaches for the treatment of diabetes.
Article in Stem cells international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells.Stem cells translational medicine · 2016Article
- Biobanking in a constantly developing medical world.TheScientificWorldJournal · 2013Review
- Diabetes treatment in 2025: can scientific advances keep pace with prevalence?Therapeutic advances in endocrinology and metabolism · 2012Article
- Human endometrial-derived mesenchymal stem cells suppress inflammation in the central nervous system of EAE mice.Stem cell reviews and reports · 2012Article
- Regulation of mesenchymal stem cell differentiation and insulin secretion by differential expression of Pdx-1.Molecular biology reports · 2012Article
- Directed differentiation of progenitor cells towards an islet-cell phenotype.American journal of stem cells · 2012Article
- Tissue engineered strategies for skeletal muscle injury.Stem cells international · 2012Review
- Advances in meniscal tissue engineering.Stem cells international · 2012Review
- Therapeutic applications of mesenchymal stroma cells in pediatric diseases: current aspects and future perspectives.Medical science monitor : international medical journal of experimental and clinical research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The incidence of diabetes and the associated debilitating complications are increasing at an alarming rate worldwide. Current therapies for type 1 diabetes focus primarily on administration of exogenous insulin to help restore glucose homeostasis. However, such treatment rarely prevents the long-term complications of this serious metabolic disorder, including neuropathy, nephropathy, retinopathy, and cardiovascular disease. Whole pancreas or islet transplantations have enjoyed limited success in some individuals, but these approaches are hampered by the shortage of suitable donors and the burden of lifelong immunosuppression. Here, we review current approaches to differentiate nonislet cell types towards an islet-cell phenotype which may be used for larger-scale cell replacement strategies. In particular, the differentiation protocols used to direct embryonic stem cells, progenitor cells of both endocrine and nonendocrine origin, and induced pluripotent stem cells towards an islet-cell phenotype are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.